Provided by Tiger Fintech (Singapore) Pte. Ltd.

Allogene Therapeutics Inc.

2.08
-0.1050-4.82%
Volume:2.64M
Turnover:5.57M
Market Cap:435.07M
PE:-1.35
High:2.20
Open:2.11
Low:2.07
Close:2.18
Loading ...

Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus

Zacks
·
08 Nov 2024

Allogene's Q3 Loss Narrower Than Expected, Sales Nil

Zacks
·
08 Nov 2024

Analysts Offer Insights on Healthcare Companies: Cartesian Therapeutics (RNAC), Allogene Therapeutics (ALLO) and Moderna (MRNA)

TIPRANKS
·
08 Nov 2024

Allogene Therapeutics Inc (ALLO) Q3 2024 Earnings Call Highlights: Financial Resilience Amidst ...

GuruFocus.com
·
08 Nov 2024

Allogene Therapeutics Inc reports results for the quarter ended in January 1 - Earnings Summary

Reuters
·
08 Nov 2024

Allogene Therapeutics Inc : Qtrly Shr Loss $0.32

THOMSON REUTERS
·
08 Nov 2024

Allogene Therapeutics Q3 2024 GAAP EPS $(0.32) Beats $(0.33) Estimate

Benzinga
·
08 Nov 2024

Allogene Therapeutics: Q3 Earnings Snapshot

Associated Press Finance
·
08 Nov 2024

Allogene Therapeutics Inc -Continues to Expect Its Cash Runway to Fund Operations Into the Second Half of 2026

THOMSON REUTERS
·
08 Nov 2024

CPRX Q3 Earnings & Revenues Beat Estimates, '24 View Raised, Stock Up

Zacks
·
07 Nov 2024

Allogene announces Phase 1 data on ALLO-316 in advanced RCC

TIPRANKS
·
07 Nov 2024

Allogene Therapeutics Inc - Allo-316 Demonstrated a Manageable Safety Profile

THOMSON REUTERS
·
07 Nov 2024

Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of Allo-316 in Heavily Pretreated Patients With Advanced Renal Cell Carcinoma at SITC and Ikcs

THOMSON REUTERS
·
07 Nov 2024

Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS

GlobeNewswire
·
07 Nov 2024

Allogene Therapeutics Inc expected to post a loss of 33 cents a share - Earnings Preview

Reuters
·
06 Nov 2024

Allogene Therapeutics to present data on ALLO-316 at IKCS, SITC meetings

TIPRANKS
·
05 Nov 2024